Evaluation of oral tegafur‐uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non‐distant metastatic TNM stage IV nasopharyngeal carcinoma
暂无分享,去创建一个
[1] F. Sung,et al. Survival outcome of patients with nasopharyngeal carcinoma: a nationwide analysis of 13 407 patients in Taiwan , 2015, Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery.
[2] D. Waxman,et al. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. , 2015, Cancer letters.
[3] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[4] Y. Shih,et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. , 2014, International journal of radiation oncology, biology, physics.
[5] G. Capellá,et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti‐tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells , 2013, International journal of cancer.
[6] Chih-Hung Hsu,et al. Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma , 2012, Oncology.
[7] B. Monk,et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.
[8] Qing Liu,et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials , 2010, BMC Cancer.
[9] Chih-Hung Hsu,et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. , 2010, Journal of Hepatology.
[10] W. Mason,et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Joaquim Bellmunt,et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). , 2010, The Lancet. Oncology.
[12] Jin-Ching Lin,et al. Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma , 2010, Clinical Cancer Research.
[13] R. McLendon,et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study , 2009, British Journal of Cancer.
[14] L. Landi,et al. Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer , 2009, Clinical Cancer Research.
[15] H. Iwata,et al. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[17] C. Tiu,et al. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer , 2007, Cancer Chemotherapy and Pharmacology.
[18] K. Shirouzu,et al. Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. , 2007, Anticancer research.
[19] V. Khoo,et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. , 2007, The Journal of urology.
[20] H. Adami,et al. The Enigmatic Epidemiology of Nasopharyngeal Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.
[21] Amanda J. Thomas,et al. A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer , 2005, Journal of pediatric hematology/oncology.
[22] S. Leung,et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. , 2005, International journal of radiation oncology, biology, physics.
[23] Jin-Ching Lin,et al. Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate? , 2004, International journal of radiation oncology, biology, physics.
[24] Yau-Huei Wei,et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.
[25] H. Kato,et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.
[26] S. Leung,et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.
[27] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[28] S. Leung,et al. Plasma Cell‐free Epstein‐Barr Virus DNA Quantitation in Patients with Nasopharyngeal Carcinoma: Correlation with Clinical Staging , 2000, Annals of the New York Academy of Sciences.
[29] M. Leblanc,et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Jin-Ching Lin,et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. , 2017, Oral oncology.
[31] G. Klement,et al. Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? , 2011, Journal of pediatric hematology/oncology.
[32] S. Groshen,et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.